Subscribe
shutterstock_728430565_casimiropt
casimiropt / Shutterstock.com
31 July 2020AmericasSarah Morgan

Humira buyers appeal AbbVie ruling to Seventh Circuit

Buyers of  AbbVie’s arthritis treatment Humira (adalimumab) have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
ITC to investigate Alvotech’s Humira biosimilar
27 January 2022   The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.
Americas
Judge refuses to block pay-for-delay law pending appeal
13 January 2020   A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Biotechnology
ITC to investigate Alvotech’s Humira biosimilar
27 January 2022   The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.
Americas
Judge refuses to block pay-for-delay law pending appeal
13 January 2020   A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

More on this story

Biotechnology
ITC to investigate Alvotech’s Humira biosimilar
27 January 2022   The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.
Americas
Judge refuses to block pay-for-delay law pending appeal
13 January 2020   A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.
Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB